CSPC PHARMA

CSPC Pharmaceutical declined roughly 2.4%, with morning weakness from 8.80 HKD to 8.51 HKD partially offset by afternoon recovery to 8.55 HKD, primarily driven by earnings disappointment. Q1 2026 EPS of 0.0855 HKD plunged 38.17% year-over-year with net profit down 38.42% to 974.8 million HKD, while revenue declined 2.43% to 7.33 billion HKD. Nomura recently cut its price target to 10.31 HKD, citing mild Q2 drug sales growth expectations. Pipeline momentum provided some offset, with FDA clearance for CRB-701's registrational trial and HA1406 enteric-coated tablets meeting its Phase III primary endpoint for depression treatment. The stock trades roughly 26.5% below its 52-week peak of 11.63 HKD yet remains above the 60-day moving average, having recovered substantially from the 52-week low of 6.53 HKD.

CSPC Pharma advanced 2.29% to HKD 8.49, driven by accelerating drug pipeline momentum and robust first-half earnings guidance. The company forecasted attributable profit of RMB 5.9–6.2 billion for H1 2026, marking record highs; key catalysts include Phase III completion of HA1406 for depression treatment with primary endpoint achieved, NMPA priority review grant for albumin-bound sirolimus injection, and recent regulatory approvals of long-acting paliperidone palmitate for schizophrenia, all transitioning toward commercialization. Q1 2026 earnings showed EPS recovering sharply to HKD 0.0855 (up 136% sequentially from Q4's 0.0361), with net profit margin expanding to 13.30%, though year-over-year EPS decline of 38.17% reflects elevated prior-year comparatives and net profit down 38.42% YoY; sequential recovery suggests cyclical operational improvement. Price-wise, the stock has rebounded over 30% from late-June lows and trades visibly above its 60-day moving average of 7.687, yet sits 27% below the 52-week high of 11.63, signaling market caution on timing of new product commercialization success.

CSPC Pharma (1093.HK) slipped 2.92% to HKD 8.30 today, weighed by a recent analyst downgrade. Nomura cut its target price to HKD 10.31 and signaled expectations for only moderate Q2 pharmaceutical sales growth, dampening sentiment around near-term profit momentum. Fundamentally, Q1 revenue of HKD 7.33 billion was essentially flat year-over-year (−2.43%), while net profit of HKD 975 million fell sharply 38.42% yoy, though net margin improved sequentially to 13.30%, hinting at stabilizing unit economics. On the tape, the stock pushed to HKD 8.55 in morning session at 09:41 BJ, then retreated into afternoon weakness, eventually touching HKD 8.29 at 14:59 BJ before settling at 8.30, a distribution pattern. The stock remains above its 60-day MA of HKD 7.69 and is down just 2.12% ytd, yet sits 28.63% below its 52-week high of HKD 11.63. The bright side: the company has been active on the pipeline, with approvals for long-acting schizophrenia injection and initiations of Phase II/III trials in oncology and rare disease, signaling innovation strength; however, profit deceleration and recent estimate cuts have temporarily overshadowed enthusiasm for these advances.

CSPC Pharmaceutical rose 2.15% today, driven by accelerating R&D pipeline progress and ongoing strategic partnerships. The stock opened at 8.39 HKD, surged to an intraday high of 8.86 HKD in the morning session, then consolidated to close at 8.55 HKD in the afternoon, with turnover of HKD 1.17 billion. The company recently obtained breakthrough therapy designation for its HER2-positive breast cancer combination therapy, while advancing multiple clinical programs: SYS 6026 injection initiated Phase II trial in China, sirolimus and SYS6043 progressing through Phase III studies. Its AstraZeneca collaboration contributed a USD25 million milestone payment. Q1 results showed sequential improvement—net profit margin expanded to 13.30% and ROE rose to 10.37%—though year-on-year metrics remained under pressure with EPS declining 38.17%. Valuation-wise, the stock trades 26.5% below its 52-week high of HKD 11.63, has gained 0.83% year-to-date, and remains above its 60-day moving average.

Sino Pharma (1093.HK) closed marginally lower at HKD8.37, down 0.36% from prior close, as profit-taking offset recent clinical catalysts. First-quarter earnings weighed on sentiment: net profit contracted 38.4% year-on-year to HKD974.8 million, while EPS fell 38.2% to HKD0.0855, explaining the near-term pressure. On the positive side, the company's clinical pipeline continues to advance with Phase III trial progression of SYS6043 and breakthrough therapy designation for HER2-positive breast cancer combinations, complemented by a USD25 million milestone payment from AstraZeneca, reinforcing partnership momentum. From a valuation perspective, the stock is only 1.3% down year-to-date but has rebounded 28.2% from its 52-week low of HKD6.53, though it remains 28% below the 52-week high of HKD11.63. Bank of America raised its target price to HKD7.60 but maintained an Underperform rating, signaling cautious expectations around earnings recovery.